P&G Macrobid cost comparisons to fluoroquinolones and Macrodantin misleading, agency says.

P&G MACROBID ANTIBIOTIC COST COMPARISONS ARE "MISLEADING", FDA says in an Oct. 28 letter from the Division of Drug Marketing, Advertising & Communications. In a promotional brochure, "P&G suggests that Macrobid [nitrofurantoin monohydrate] is as effective as fluoroquinolones in treating acute cystitis and costs less. However, the graphic presentation fails to reveal material facts concerning the efficacy rates and costs of other medications that may be comparable or superior to Macrobid in treating acute cystitis, but cost less," the letter states.